JP2021503455A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021503455A5 JP2021503455A5 JP2020526566A JP2020526566A JP2021503455A5 JP 2021503455 A5 JP2021503455 A5 JP 2021503455A5 JP 2020526566 A JP2020526566 A JP 2020526566A JP 2020526566 A JP2020526566 A JP 2020526566A JP 2021503455 A5 JP2021503455 A5 JP 2021503455A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- cdr2
- cdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017111712 | 2017-11-17 | ||
| CNPCT/CN2017/111712 | 2017-11-17 | ||
| PCT/CN2018/115213 WO2019096121A1 (en) | 2017-11-17 | 2018-11-13 | Single-domain antibodies and variants thereof against pd-l1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021503455A JP2021503455A (ja) | 2021-02-12 |
| JP2021503455A5 true JP2021503455A5 (https=) | 2021-12-09 |
| JP7410024B2 JP7410024B2 (ja) | 2024-01-09 |
Family
ID=66538525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526566A Active JP7410024B2 (ja) | 2017-11-17 | 2018-11-13 | Ｐｄ－ｌ１に対する単一ドメイン抗体とその多様体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11673954B2 (https=) |
| EP (1) | EP3710480A4 (https=) |
| JP (1) | JP7410024B2 (https=) |
| KR (1) | KR102810657B1 (https=) |
| CN (1) | CN111433224B (https=) |
| AU (1) | AU2018366650B2 (https=) |
| CA (1) | CA3081375A1 (https=) |
| IL (1) | IL274438A (https=) |
| SG (1) | SG11202004144VA (https=) |
| TW (1) | TW201923083A (https=) |
| WO (1) | WO2019096121A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112399973B (zh) * | 2018-06-05 | 2022-12-16 | 江苏康宁杰瑞生物制药有限公司 | 二聚体及其用途 |
| CN112409483B (zh) * | 2019-08-22 | 2024-08-27 | 浙江道尔生物科技有限公司 | 抗pd-l1纳米抗体 |
| CN115947846A (zh) * | 2019-09-12 | 2023-04-11 | 普米斯生物技术(珠海)有限公司 | 一种抗pd-l1纳米抗体及其衍生物和用途 |
| WO2021057836A1 (en) | 2019-09-25 | 2021-04-01 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| WO2021083335A1 (zh) * | 2019-10-30 | 2021-05-06 | 三优生物医药(上海)有限公司 | Pd-l1结合分子 |
| WO2021139776A1 (en) | 2020-01-10 | 2021-07-15 | Shanghai Henlius Biotech, Inc. | Anti-tigit antibodies, multispecific antibodies comprising the same and methods of using the same |
| JP7512413B2 (ja) * | 2020-03-31 | 2024-07-08 | ビオテウス・インコーポレイテッド | 抗ｐｄ－ｌ１およびｐｄ－ｌ２抗体ならびにその誘導体および用途 |
| CN113527488B (zh) * | 2020-04-22 | 2026-04-17 | 迈威(上海)生物科技股份有限公司 | 一种靶向人程序性死亡配体1（pd-l1）的单可变域抗体及其衍生物 |
| CN114106190B (zh) | 2020-08-31 | 2025-04-08 | 普米斯生物技术(珠海)有限公司 | 一种抗vegf/pd-l1双特异性抗体及其用途 |
| EP3992208A1 (en) * | 2020-11-03 | 2022-05-04 | Randox Laboratories Ltd | Anti-pd-l1 vhh antibodies |
| JP2023552462A (ja) * | 2020-12-08 | 2023-12-15 | ジャナックス セラピューティクス，インク． | 半減期延長組成物および方法 |
| AU2021396172A1 (en) | 2020-12-09 | 2023-07-06 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| US11685784B2 (en) * | 2021-03-24 | 2023-06-27 | China Medical University Hospital | Anti-immune-checkpoint nanobody and nucleic acid encoding sequence thereof, and uses of the same |
| EP4349867A4 (en) * | 2021-05-28 | 2026-01-07 | Harbour Biomed Shanghai Co Ltd | SPECIFIC BINDING PROTEIN TARGETING PD-L1 AND CD73 |
| CN113045662B (zh) * | 2021-05-31 | 2021-08-13 | 西宝生物科技（上海）股份有限公司 | 一种特异性识别pd-l1的纳米抗体及其应用 |
| CN116547006B (zh) * | 2021-08-06 | 2024-09-20 | 贝达药业股份有限公司 | 抗pd-l1纳米抗体及其应用 |
| CN116547300B (zh) * | 2021-09-30 | 2024-10-08 | 贝达药业股份有限公司 | 双特异性抗体及其应用 |
| CN116410314A (zh) * | 2021-12-31 | 2023-07-11 | 博生吉医药科技(苏州)有限公司 | 一种新型pdl1单域抗体的开发 |
| CN118401564A (zh) * | 2022-01-18 | 2024-07-26 | Fbd生物制品有限公司 | 靶向cd47/pd-l1的蛋白质复合物和其使用方法 |
| AU2023419584A1 (en) * | 2022-12-29 | 2025-06-26 | Shanghai Henlius Biologics Co., Ltd. | Anti-pdl1 antibodies and methods of use |
| CN120603849A (zh) * | 2023-01-18 | 2025-09-05 | 科望(苏州)生物医药科技有限公司 | 抗pdl1单域抗体、融合蛋白及其用途 |
| EP4490201A4 (en) * | 2023-05-31 | 2026-03-11 | Fbd Biologics Ltd | CD47/PD-L1 Targeted Protein Complex and Its Methods of Use |
| WO2025034806A1 (en) | 2023-08-08 | 2025-02-13 | Wisconsin Alumni Research Foundation | Single-domain antibodies and variants thereof against fibroblast activation protein |
| WO2025178959A1 (en) | 2024-02-20 | 2025-08-28 | University Of Georgia Research Foundation, Inc. | Single-domain antibodies and variants thereof against tab1 |
| WO2026030445A1 (en) | 2024-07-30 | 2026-02-05 | Wisconsin Alumni Research Foundation | Degradation targeting agents and uses thereof |
| CN119119278B (zh) * | 2024-10-29 | 2025-03-21 | 海南大学 | 一种抗pd-l1蛋白的纳米抗体及其制备方法和应用 |
| CN119874915B (zh) * | 2025-01-23 | 2025-11-18 | 百吉生物医药(广州)股份有限公司 | 一种程序性死亡受体1的纳米抗体及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2963712A1 (en) | 2014-10-21 | 2016-04-28 | Ablynx Nv | Treatment of il-6r related diseases |
| CN106243225B (zh) * | 2015-06-11 | 2021-01-19 | 智翔（上海）医药科技有限公司 | 新型抗-pd-l1抗体 |
| CN106397592A (zh) * | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
| AU2016355569B2 (en) | 2015-11-18 | 2020-01-02 | Merck Sharp & Dohme Llc | CTLA4 binders |
| KR20180080337A (ko) | 2015-11-27 | 2018-07-11 | 아블린쓰 엔.브이. | Ｃｄ40ｌ을 억제하는 폴리펩티드 |
| CN106939047B (zh) | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
| KR20180096789A (ko) * | 2016-01-11 | 2018-08-29 | 인히브릭스, 인크. | 다가 및 다중특이적 41bb-결합 융합 단백질 |
| CN107216389B (zh) * | 2016-03-18 | 2022-03-29 | 和迈生物科技有限公司 | 抗pd-l1纳米抗体及其编码序列和用途 |
| SG11201809336QA (en) | 2016-05-09 | 2018-11-29 | Igm Biosciences Inc | Anti-pd-l1 antibodies |
-
2018
- 2018-11-13 EP EP18877388.1A patent/EP3710480A4/en active Pending
- 2018-11-13 SG SG11202004144VA patent/SG11202004144VA/en unknown
- 2018-11-13 WO PCT/CN2018/115213 patent/WO2019096121A1/en not_active Ceased
- 2018-11-13 JP JP2020526566A patent/JP7410024B2/ja active Active
- 2018-11-13 US US16/764,411 patent/US11673954B2/en active Active
- 2018-11-13 AU AU2018366650A patent/AU2018366650B2/en active Active
- 2018-11-13 CN CN201880074389.0A patent/CN111433224B/zh active Active
- 2018-11-13 CA CA3081375A patent/CA3081375A1/en active Pending
- 2018-11-13 KR KR1020207016959A patent/KR102810657B1/ko active Active
- 2018-11-16 TW TW107140889A patent/TW201923083A/zh unknown
-
2020
- 2020-05-04 IL IL274438A patent/IL274438A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021503455A5 (https=) | ||
| CN111454357B (zh) | 一种含有抗体的肿瘤治疗剂的开发和应用 | |
| US10913796B2 (en) | Antibodies targeting Fc receptor-like 5 and methods of use | |
| JP2021508469A5 (https=) | ||
| JP2019533719A5 (https=) | ||
| Revets et al. | Nanobodies as novel agents for cancer therapy | |
| JP2021510521A5 (https=) | ||
| JP7649744B2 (ja) | Ｂｔｎ３ａ結合タンパク質及びその使用 | |
| JP2013515508A5 (https=) | ||
| JP2021520832A5 (https=) | ||
| JP2018522888A5 (https=) | ||
| JP2012525829A5 (https=) | ||
| HRP20241013T1 (hr) | Protutijela za kelatirane radionuklide | |
| CA3196809A1 (en) | Combination treatment | |
| JP2018093875A5 (https=) | ||
| JP2013545738A5 (https=) | ||
| US20240117035A1 (en) | Cldn18.2/cd3 bispecific antibodies for the therapy of cldn18.2-expressing solid tumors | |
| JP2021508707A5 (https=) | ||
| JP2024532489A5 (https=) | ||
| CN114667296B (zh) | 一种双特异性抗体及其用途 | |
| JP2020515277A5 (https=) | ||
| JP2024001073A5 (https=) | ||
| WO2022171100A1 (zh) | Gpc3人源化抗体及其应用 | |
| WO2022002033A1 (zh) | 具有H2L2与HCAb结构的结合蛋白 | |
| JP2021511387A5 (https=) |